Diabetes Devices Market Reports

In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased significantly in value. Abbott received CE Mark approval for FreeStyle® Libre in September 2014 and for FreeStyle® 2 in October 2018. The company also launched FGM in the U.S. market in late 2017 and has expanded to numerous international

Throughout this medical market research, we analyzed over 90 diabetes companies across 16 countries and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. While this MedSuite report contains all the Global Diabetes Monitoring, Treatment and Drug Delivery data and analysis, each of the market segments

In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM in late 2017. Abbott received FDA approval for FreeStyle® Libre in September 2017 and for FreeStyle® Libre 14 Day in July 2018. The

Industry Trends Patent expirations and the introduction of new products will lead to higher unit sales growth in the long-acting insulin segment, relative to the rapid-acting insulin, premixed insulin and human insulin segments. Combined with steady appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total insulin

About MedCore Research Our analysts meticulously research for up to 3 to 4 months to put together one suite of reports (MedSuite), which is a comprehensive analysis of a group of healthcare markets. MedCore research is one portion of that analysis that focuses on one market segment and provides further detailed segmentation to get a

Blood glucose meters are electronic devices that analyze a small drop of blood drawn using a lancet and lancing device. The blood is placed on a small disposable test strip that is inserted into the blood glucose meter, which reads the level of glucose in the blood. The blood glucose meter is battery-powered and fits in the palm of the hand. When the blood is placed on the strip, it flows in through capillary action. The electrochemical reaction between the test strip and the blood determines the blood glucose concentration reported as milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L).

Blood glucose test strips are thin strips with enzymes that react to blood droplets. These create either a photometric or electrochemical response which is read by a glucose meter. Strips vary by size, chemical makeup, fluid channels, etc. and are typically sold in containers of 50 or 100. A single strip is used for each test, and some brands have preloaded strip storage within their meters. Electrochemical strips are the most popular type, largely due to the extremely small volumes of blood required to measure glucose. These strips function by working with the blood glucose meter to produce an electrical current, which is proportional to the blood glucose concentration. Several different enzymes may be used for transferring electrons from the glucose in the blood to the electrode. Typically, the current can be measured between 5 and 15 seconds.

Continuous glucose monitoring (CGM) allows for a more accurate reading of how blood glucose levels fluctuate throughout the day by measuring interstitial glucose levels on a continuous basis and estimating blood glucose levels based on these readings. A CGM system is typically made up of three components: a glucose sensor, transmitter and receiver. The sensor is inserted under the skin into the interstitial fluid and held with an adhesive. Sensors are typically sold in groups of four and are labeled for six to seven days of use, depending on the manufacturer. A transmitter takes the glucose reading from the sensor and wirelessly sends it to a small, hand-held receiver. If glucose levels are too low or high, the receiver warns the patient. Some manufacturers have even built-in a threshold audible alarm as a fixed safety feature when the patient approaches levels below 55 mg/dL, at which point the patient is still interactive but severely hypoglycemic.

Insulin is a protein and when administered orally, it degrades in the stomach and the intestines. When administered subcutaneously, it is better absorbed and has more of an effect on blood sugar levels. Although many alternative technologies have entered the insulin delivery device market, such as insulin pumps and insulin pens, syringes are still the most widely used device to inject insulin. Insulin syringes are moving from being hypodermic to those with finer points. Syringes are used with 10 mL insulin vials and come in 0.3 mL, 0.5 mL and 1 mL calibrations. In addition, thinner and shorter syringes are becoming more popular in the market, as they cause less discomfort when giving an injection. Needle thickness is indicated by gauge number; the higher the gauge number, the thinner the needle.

A lancet is a small needle with a plastic or rubber coating that fits into the top of a lancing device. Lancing devices are pen-like instruments which are used in conjunction with a lancet to draw blood to be applied to a glucose strip. Many lancets come as a component of blood glucose monitoring kits, and can be adjusted for injection depth. Reusable lancets are not as effective as they are more dull and painful and increase the risk of infection.

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.

Blood glucose meters are electronic devices that analyze a small drop of blood that is drawn using a lancet and lancing device. The blood is placed on a small disposable test strip that is inserted into the blood glucose meter, which reads the level of glucose in the blood. The blood glucose meter is battery-powered and fits in the palm of the hand. When the blood is placed on the strip, it flows in through capillary action. The electrochemical reaction between the test strip and the blood determines the blood glucose concentration reported as milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L).

Blood glucose test strips are thin strips with enzymes that react to blood droplets. These create either a photometric or electrochemical response which is read by a glucose meter. Strips vary by size, chemical makeup, fluid channels, etc. and are typically sold in containers of 50 or 100. A single strip is used for each test, and some brands have preloaded strip storage within their meters. Electrochemical strips are the most popular type, largely due to the extremely small volumes of blood required to measure glucose. These strips function by working with the blood glucose meter to produce an electrical current, which is proportional to the blood glucose concentration. Several different enzymes may be used for transferring electrons from the glucose in the blood to the electrode. Typically, the current can be measured in between 5 to 15 seconds.

Continuous glucose monitoring (CGM) allows for a more accurate reading of how blood glucose levels fluctuate throughout the day by measuring interstitial glucose levels on a continuous basis and estimating blood glucose levels based on these readings.
The CGM system is typically made up of three components: a glucose sensor, transmitter and receiver. The sensor is inserted under the skin into the interstitial fluid and held with an adhesive. Sensors are typically sold in groups of four and are labeled for three to seven days of use, depending on the manufacturer. A transmitter takes the glucose reading from the sensor and wirelessly sends it to a small, hand-held receiver. If glucose levels are too low or high, the receiver warns the patient. Some manufacturers have even built-in a threshold audible alarm as a fixed safety feature when the patient approaches levels below 55 mg/dL, at which point the patient is still interactive but severely hypoglycemic.

The FGM system is made up of two components: a sensor and an electronic reader device that takes readings of glucose levels from the sensor. Sensors are worn on the back of the upper arm of patients for up to 14 days and inserted in a similar fashion as CGM sensors, with an adhesive to hold it in place. The reader component is manually placed over the sensor and after about a second, the reader displays a measurement of the patient’s glucose level, a historical trend of previous scans and the direction in which the glucose level is moving. A recent product update allows patients to use near-field communication (NFC) technology to substitute their smartphones as the reader component, eliminating the need to purchase the dedicated reader device. The FGM system is also factory calibrated which removes the need for routine fingersticks; something that is not available in current CGM systems. These features are popular with patients who cite “the pain, inconvenience and indiscretion” of fingersticking as the primary reasons for not managing their diabetes as efficiently and proactively as they should.

Insulin is a hormone that causes glucose uptake from the blood through the cells of the liver, muscle and fat tissue to be stored as glycogen in the liver and muscle. Type 1 diabetics’ immune systems destroy pancreatic beta cells: the only cells that can make insulin. The body therefore fails to produce insulin and cannot naturally convert food into energy. Type 2 diabetics have a resistance to insulin, and cells are not able to use the insulin present in the body. The need for insulin increases to the point that the pancreas can no longer produce it. Insulin is therefore a mode of treating both type 1 and type 2 diabetes.